Skip to main content

Pravin Anand and Aditya Gupta explain the errors the Controller General of Patents made in granting a compulsory licensing order to Bayer.

The affordability of pharmaceuticals has been at the centre of the patent debate in India, with courts, industry stakeholders, academics and the media regularly commenting on the comparative price of drugs marketed by innovators and generics.

This debate has reignited with India issuing its first compulsory licensing order in the post TRIPS era. The order has had wide ramifications for the Indian pharmaceutical industry, with the generic companies engaging in so called pricing wars. It has received attention the world over with comments from governmental agencies, industry stakeholders and the media.

This article was published in IP Focus 2012.

Read more

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
•
Nov 18, 2026

A few seconds of weather footage broadcast in New Delhi ended up at the center of a federal copyright lawsuit in California. A news broadcaster based in

Can Foreign Copyright Owners Sue Indian Broadcasters Abroad? The Territorial Reach of Copyright Disputes
News & Updates, Thought Leadership
•
Nov 14, 2026

Generative artificial intelligence systems are trained on large volumes of information, including text, images, news articles and other digital material.

Can AI Training be Copyright Infringement? The ANI v. OpenAI Dispute in India
News & Updates, Thought Leadership
•
Nov 11, 2026

Think about the apps you use every day. Their visual identity is often the first thing you recognise: the arrangement of icons, navigation menus, buttons,

Can You Patent the Look of an App? GUI and Icon Protection in India
News & Updates, Thought Leadership
•
Nov 09, 2026

‘First published on Chambers’ By: Dhruv Anand, Dhananjay Khanna and Bhavya Verma It will not be an exaggeration to say that there has been an explosion

PERSONALITY RIGHTS – CURRENT TRENDS